Saussele, S. Richter, J. Guilhot, J. Gruber, F.X. Hjorth-Hansen, H. Almeida, A. Janssen, J.J.W.M. Mayer, J. Koskenvesa, P. Panayiotidis, P. Olsson-Strömberg, U. Martinez-Lopez, J. Rousselot, P. Vestergaard, H. Ehrencrona, H. Kairisto, V. Machová Poláková, K. Müller, M.C. Mustjoki, S. Berger, M.G. Fabarius, A. Hofmann, W.-K. Hochhaus, A. Pfirrmann, M. Mahon, F.-X. Ossenkoppele, G. Pagoni, M.N. Söderlund, S. Escoffre-Barbe, M. Etienne, G. Dengler, J. Huguet, F. von Bubnoff, N. Klamova, H. Faber, E. Guilhot, F. Lotfi, K. Rea, D. Brümmendorf, T.H. de Greef, G.E. Stenke, L. Nicolini, F.E. Legros, L. Burchert, A. Voglova, J. Charbonnier, A. Gyan, E. Kunzmann, V. Westerweel, P.E. EURO-SKI investigators, Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial, The lancet oncology, (19), 747-757, 2018, The Lancet Publishing Group,